Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females 18 years of age and above on the day of enrollment;~2. Individuals in good health~3. Individuals are able to comply with all study procedures~4. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.~Exclusion Criteria:~1. Individual not able to comprehend and to follow all required study procedures;~2. History or any illness that might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;~3. Any serious chronic or progressive disease according to judgment of the investigator~4. History of any anaphylaxis, serious vaccine reactions, to any excipients.~5. Adjuvanted influenza vaccine or documented confirmed or suspected influenza disease within 3 months prior to Day 1;~6. Receipt of another investigational agent within 4 weeks prior to enrollment, or before completion of the safety follow-up period in this or in another study; unwilling to refuse participation in another clinical study through the end of this study;~7. Any other vaccines within 4 weeks prior to enrollment or who are planning to receive any vaccine within 4 weeks from the study vaccines; only exception being plain seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week study vaccinations.~8. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks;~9. Axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination;~10. Known or suspected impairment/alteration of immune function, for example resulting from a receipt of immunosuppressive therapy within 60 days prior to Visit 1;~11. History of progressive or severe neurological disorders;~12. Surgery planned during the study period that in the Investigator's opinion would interfere with the study visits schedule;~13. Female of childbearing potential, not used any acceptable contraceptive methods for at least 2 months prior to study entry;~14. Female pregnant or nursing (breastfeeding) mothers or females of childbearing potential do not plan to use acceptable birth control measures during the first 3 weeks after vaccination;~15. Members of the research staff or their relatives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- low dose of antigen + low dose of adjuvant (Type: EXPERIMENTAL): None
- high dose of antigen + high dose of adjuvant (Type: EXPERIMENTAL): None
- high dose of antigen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).